{"entity":{"id":"eric-klein","kind":"person","name":"Eric A. Klein","aka":[],"tldr":"Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.","summary":"Eric Klein led the Circulating Cell-free Genome Atlas (CCGA) study that developed and clinically validated the Galleri cell-free DNA methylation test for detecting more than 50 cancer types and predicting tissue of origin, the basis for the PATHFINDER and NHS-Galleri trials. As a urologist he led the SELECT prevention trial and the development of the Oncotype DX prostate score.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection"}],"tags":["early-detection","mced","prostate"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["mced","methylation-profiling"],"targets":[],"drugs":["galleri"],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":["nhs-galleri","pathfinder-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-pathfinder-lancet-2023"],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Emeritus Professor and Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic; Distinguished Scientist, GRAIL","institutionId":"cleveland-clinic","specialisms":["Multi-cancer early detection","Prostate cancer","Genomic classifiers","Urologic oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection"}],"papers":[{"title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (CCGA)","journal":"Annals of Oncology","year":2021,"doi":"10.1016/j.annonc.2021.05.806"},{"title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","journal":"JAMA","year":2011,"doi":"10.1001/jama.2011.1437"},{"title":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)01700-2","doi":"10.1016/S0140-6736(23)01700-2"}]},"route":"/people/eric-klein/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"institution":[{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/"}],"trial":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/"},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/"}],"paper":[{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}]}}